RBD SARS-CoV-2 HBsAg VLP vaccine Uses, Dosage, Side Effects and more
Receptor binding domain SARS-CoV-2 Hepatitis B surface antigen virus-like particle vaccine (RBD SARS-CoV-2 HBsAg VLP vaccine), is a virus-like particle vaccine candidate where the RBD antigen is conjugated to the hepatitis B surface antigen. Virus-like particles (VLPs) are protein-based vaccines that stimulate high immune responses because of the VLPs’ repetitive structures. Regarding this vaccine specifically, it stimulates the immune system to produce anti-receptor binding domain antibodies.
| Attribute | Details |
|---|---|
| Trade Name | RBD SARS-CoV-2 HBsAg VLP vaccine |
| Generic | Receptor binding domain (RBD) SARS-CoV-2 (COVID-19) hepatitis B surface antigen (HBsAg) virus-like particle (VLP) vaccine |
| Receptor binding domain (RBD) SARS-CoV-2 (COVID-19) hepatitis B surface antigen (HBsAg) virus-like particle (VLP) vaccine Other Names | RBD SARS-CoV-2 HBsAg VLP vaccine |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
